581 related articles for article (PubMed ID: 20371691)
21. Gamma/delta T cell antigen receptors expressed on tumor-infiltrating lymphocytes from patients with solid tumors.
Nanno M; Seki H; Mathioudakis G; Suzuki R; Itoh K; Ioannides CG; Suzuki S; Chen PF; Platsoucas CD
Eur J Immunol; 1992 Mar; 22(3):679-87. PubMed ID: 1312472
[TBL] [Abstract][Full Text] [Related]
22. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma.
Gaudin C; Kremer F; Angevin E; Scott V; Triebel F
J Immunol; 1999 Feb; 162(3):1730-8. PubMed ID: 9973436
[TBL] [Abstract][Full Text] [Related]
23. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
Mulders P; Tso CL; Gitlitz B; Kaboo R; Hinkel A; Frand S; Kiertscher S; Roth MD; deKernion J; Figlin R; Belldegrun A
Clin Cancer Res; 1999 Feb; 5(2):445-54. PubMed ID: 10037196
[TBL] [Abstract][Full Text] [Related]
24. Restriction of the T-cell repertoire in tumor-infiltrating lymphocytes from nine patients with renal-cell carcinoma. Relevance of the CDR3 length analysis for the identification of in situ clonal T-cell expansions.
Puisieux I; Bain C; Merrouche Y; Malacher P; Kourilsky P; Even J; Favrot M
Int J Cancer; 1996 Apr; 66(2):201-8. PubMed ID: 8603812
[TBL] [Abstract][Full Text] [Related]
25. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.
Viey E; Lucas C; Romagne F; Escudier B; Chouaib S; Caignard A
J Immunother; 2008 Apr; 31(3):313-23. PubMed ID: 18317356
[TBL] [Abstract][Full Text] [Related]
26. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity.
van der Veken LT; Hagedoorn RS; van Loenen MM; Willemze R; Falkenburg JH; Heemskerk MH
Cancer Res; 2006 Mar; 66(6):3331-7. PubMed ID: 16540688
[TBL] [Abstract][Full Text] [Related]
27. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
[TBL] [Abstract][Full Text] [Related]
28. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
29. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
Cole DJ; Wilson MC; Rivoltini L; Custer M; Nishimura MI
Cancer Res; 1997 Dec; 57(23):5320-7. PubMed ID: 9393756
[TBL] [Abstract][Full Text] [Related]
30. In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma.
Gaudin C; Dietrich PY; Robache S; Guillard M; Escudier B; Lacombe MJ; Kumar A; Triebel F; Caignard A
Cancer Res; 1995 Feb; 55(3):685-90. PubMed ID: 7834641
[TBL] [Abstract][Full Text] [Related]
31. Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma.
Xu Y; Morales AJ; Cargill MJ; Towlerton AMH; Coffey DG; Warren EH; Tykodi SS
Cancer Immunol Immunother; 2019 Dec; 68(12):1979-1993. PubMed ID: 31686124
[TBL] [Abstract][Full Text] [Related]
32. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition.
Pandolfi F; Boyle LA; Trentin L; Kurnick JT; Isselbacher KJ; Gattoni-Celli S
Cancer Res; 1991 Jun; 51(12):3164-70. PubMed ID: 1904004
[TBL] [Abstract][Full Text] [Related]
33. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
34. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
Lamers CH; van Elzakker P; Langeveld SC; Sleijfer S; Gratama JW
Cytotherapy; 2006; 8(6):542-53. PubMed ID: 17148030
[TBL] [Abstract][Full Text] [Related]
35. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes.
Engels B; Noessner E; Frankenberger B; Blankenstein T; Schendel DJ; Uckert W
Hum Gene Ther; 2005 Jul; 16(7):799-810. PubMed ID: 16000062
[TBL] [Abstract][Full Text] [Related]
36. Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma.
Wang QJ; Hanada K; Feldman SA; Zhao Y; Inozume T; Yang JC
J Immunol Methods; 2011 Mar; 366(1-2):43-51. PubMed ID: 21255579
[TBL] [Abstract][Full Text] [Related]
37. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.
Mulders P; Tso CL; Pang S; Kaboo R; McBride WH; Hinkel A; Gitlitz B; Dannull J; Figlin R; Belldegrun A
J Immunother; 1998 May; 21(3):170-80. PubMed ID: 9610908
[TBL] [Abstract][Full Text] [Related]
38. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
39. Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
Brouwenstijn N; Gaugler B; Krüse KM; van der Spek CW; Mulder A; Osanto S; van den Eynde BJ; Schrier PI
Int J Cancer; 1996 Oct; 68(2):177-82. PubMed ID: 8900424
[TBL] [Abstract][Full Text] [Related]
40. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.
Oren R; Hod-Marco M; Haus-Cohen M; Thomas S; Blat D; Duvshani N; Denkberg G; Elbaz Y; Benchetrit F; Eshhar Z; Stauss H; Reiter Y
J Immunol; 2014 Dec; 193(11):5733-43. PubMed ID: 25362181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]